# A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06895928/  
OnCo record `nct06895928` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SHR-A2102, Bevacizumab and Osimertinib in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors is a phase 2 interventional study registered as NCT06895928 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 400 participants planned, started 2025-03-28 and due to reach its primary completion in 2028-12. Interventions recorded: SHR-A2102, Bevacizumab Injection, Adebelimab Injection, Ametinib Mesylate Tablets and Osimertinib Mesylate Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06895928
- Phase: 2
- Setting: A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT06895928: https://clinicaltrials.gov/study/NCT06895928

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06895928.json